Список литературы к циклу статей: Болезнь Крона, часть III

Иван Пожаров24 февраля, 23:12

46. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH et al. A comparison of 
methotrexate with placebo for the maintenance of remission in Crohn's disease. North American 
Crohn's Study Group Investigators. N Engl J Med 2000;342(22):1627-32.
47. National Institute for Health and Clinical Excellence. Infliximab (review) and adalimumab for the 
treatment of Crohn's disease Includes a review of NICE technology appraisal guidance 40. 2010. 25-7-
2010.
48. Rutgeerts P, Van AG, Vermeire S. Review article: Infliximab therapy for inflammatory bowel 
disease--seven years on. Aliment Pharmacol Ther 2006;23(4):451-63.
49. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al. Maintenance 
infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541-9.
50. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D et al. Human anti-
tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. 
Gastroenterology 2006;130(2):323-33.
51. Sands BE, Blank MA, Patel K, Van Deventer SJ. Long-term treatment of rectovaginal fistulas in 
Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 
2004;2(10):912-20.
52. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE et al. Infliximab for the 
treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 
2006;55(4):505-9.
53. D'Haens G, Baert F, Van AG, Caenepeel P, Vergauwe P, Tuynman H et al. Early combined 
immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an 
open randomised trial. Lancet 2008;371(9613):660-7.
54. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D et al. 
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362(15):1383-
95.
55. Gisbert JP. Safety of immunomodulators and biologics for the tretament of inflammatory bowel 
disease during pregnancy and breast-feeding. Inflammatory Bowel Dis 2010;16(5):881-95.
56. Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M. Long-term antibiotic treatment for 
Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis 
2010;50(4):473-80.
57. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of broad-spectrum antibiotic therapy 
in patients with active Crohn's disease.Clin Ther 2006;28(12):1983-8.
58. Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M. Long-term antibiotic treatment for 
Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis 
2010;50(4):473-80.
59. Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A et al. European evidence 
based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006;55 
Suppl 1:i36-i58.
60. Lochs H. To feed or not to feed? Are nutritional supplements worthwhile in active Crohn's 
disease? Gut 2006;55(3):306-7.
61. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for inducing remission of Crohn's 
disease. Cochrane Database Syst Rev2001;(3):CD000542.
62. Gorard DA. Enteral nutrition in Crohn's disease: fat in the formula. Eur J Gastroenterol Hepatol 
2003;15(2):115-8.
63. Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary 
treatment of anal fistulae in Crohn's disease. Gut1980;21(6):525-7.
64. Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or 
dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006;(2):CD000279.
65. Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Intestinal and extra-intestinal cancer in 
Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment 
Pharmacol Ther 2004;19(3):287-93.